
    
      A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to
      evaluate the efficacy and safety of dociparstat sodium in combination with standard intensive
      induction and consolidation chemotherapy for the treatment of newly-diagnosed AML patients.
    
  